Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation
Conditions
Interventions
Tesamorelin
Placebo for Tesamorelin
Locations
47
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Body Positive Inc.
Phoenix, Arizona, United States
Somero, Michael
Indio, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Office of Dr. Michael Somero
Palm Springs, California, United States
University of California
San Francisco, California, United States
Start Date
August 1, 2007
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
September 30, 2022
NCT03087253
NCT05996536
NCT04142047
NCT06694805
NCT07428330
NCT07225530
Lead Sponsor
Theratechnologies
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions